<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228523</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/19/0183</org_study_id>
    <secondary_id>2019-A02754-53</secondary_id>
    <nct_id>NCT04228523</nct_id>
  </id_info>
  <brief_title>Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED)</brief_title>
  <acronym>ETPARK-REMED</acronym>
  <official_title>Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>France Parkinson Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dopaminergic drug can have adverse effects leading to potential serious consequences.
      Therapeutic patient education must promote the understanding of drugs to improve its
      management. This study tries to evaluate the effect of therapeutic education workshop on
      Parkinson disease's drug (drug workshop) on the evolution of drug's representations in
      patients with Parkinson's disease compared to a control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dopaminergic drug can have adverse effects leading to potential serious consequences.
      Therapeutic patient education must promote the understanding of drugs to improve its
      management.

      The therapeutic educational program ETPARK includes individual's consults or workshop. The
      team frequently offer to patients to participate in workshop on Parkinson disease's drug.

      This study tries to evaluate the effect of therapeutic education workshop on Parkinson
      disease's drug (drug workshop) on the evolution of drug's representations in patients with
      Parkinson's disease compared to a control group (speaking group) at 1 and 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>therapeutic education or speaking group</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of Drug representation in Patients : BMQ</measure>
    <time_frame>Three months</time_frame>
    <description>Evolution of Drug representation through the Believe about Medicines Questionnaire (BMQ) compared to the control group. Evolution will be compared between the Baseline and the end of the study
BMQ with eighteen items coded from 1 &quot; &quot;strongly agree&quot; to 5 &quot;strongly disagree&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evolution of Drug representation in Patients : Verbal association</measure>
    <time_frame>Three months</time_frame>
    <description>Evolution of Drug representation through verbal association tasks compared to the control group. Evolution will be compared between the Baseline and the end of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug representation in caregivers : Verbal association</measure>
    <time_frame>Day 1</time_frame>
    <description>Drug representation through verbal association tasks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug representation in caregivers : BMQ</measure>
    <time_frame>Day 1</time_frame>
    <description>Drug representation through the Believe about Medicines Questionnaire (BMQ). BMQ with eighteen items coded from 1 &quot; &quot;strongly agree&quot; to 5 &quot;strongly disagree&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knowledge about the disease</measure>
    <time_frame>three months</time_frame>
    <description>Evolution between Baseline and three months with a test created for the study. The test have 8 questions with two answers possible : True or False</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution in life quality : VAS</measure>
    <time_frame>three months</time_frame>
    <description>Evolution in life quality evaluate with Visual Analog Scale (VAS), 0 being the worst quality of life and 10 the best quality of life he can have.
Evolution between Baseline and three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution in life quality : PDQ-(39)</measure>
    <time_frame>three months</time_frame>
    <description>Evolution in life quality evaluate with Parkinson Disease Quotation (PDQ)-39 with thirty-nine items coded from 1 &quot; &quot;always&quot; to 5 &quot;never&quot;. The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living including relationships, social situations and communication.
Evolution between Baseline and three months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Therapeutic education workshop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two group receive therapeutic education workshop already existing in Toulouse University Hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Speaking Therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One group receive speaking therapy already existing in Toulouse University Hospital</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapeutic education workshop</intervention_name>
    <description>Workshop on Parkinson disease drug has several educative sequences (lasting 4hours).
A first round table is organized to know the needs and issues related to drug management of patients.
The 1st educative sequence consists in knowing the different class of dopaminergic drugs and their action.
The 2nd educative sequence leads patients to understand their prescription and be aware of the needs to take pills regularly.
The 3rd educative sequence consists in learning and identifying potentials adverse effects and finds effective strategies to prevent them.
At the end, one patient explains its tips and tricks about its drug management</description>
    <arm_group_label>Therapeutic education workshop</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Speaking Therapy</intervention_name>
    <description>Speaking group is leaded by a psychologist from Centre Expert Parkinson (lasting 2 hours). This specific time is an exchange between patients with Parkinson disease who feel free to come. It is about sharing its own experience. It is a very special moment, confidential and kindly where patients don't judge themselves and speak only if they want to.</description>
    <arm_group_label>Speaking Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Parkinson's disease according to the United Kingdom Parkinson Disease
             Society Brain Bank (UKPDSBB) criteria,

          -  Patients who are already in therapeutic education program ETPARK,

          -  Patients who need and want to participate in therapeutic education workshop on
             Parkinson disease drug,

          -  Patients with health insurance,

          -  Patients who have signed a written informed consent form.

        Exclusion Criteria:

          -  Patients suffering from another parkinsonian syndrome (multiple system atrophy,
             progressive supranuclear palsy etc.),

          -  Patients who has already done workshop on Parkinson disease drug (program ETPARK)

          -  Patients already included in clinical trial during the study,

          -  Patients who have severe psychiatric disorders or dopaminergic psychosis,

          -  Patients with cognitive impairment,

          -  Patients unable to complete the various scales used in the study,

          -  Patients under juridical protection,

          -  Women pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Brefel-Courbon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy Hospital Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Brefel-Courbon, MD, PHD</last_name>
    <phone>05 61 14 59 62</phone>
    <phone_ext>33</phone_ext>
    <email>christine.brefel-courbon@univ-tlse3.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Toulouse University Hospital</name>
      <address>
        <city>Toulouse</city>
        <state>Occitanie</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christine Brefel-courbon, MD PhD</last_name>
      <phone>05 61 14 59 62</phone>
      <phone_ext>33</phone_ext>
      <email>christine.brefel-courbon@univ-tlse3.fr</email>
    </contact>
    <investigator>
      <last_name>Fabienne Ory Magne, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Canivet C, Costa N, Ory-Magne F, Arcari C, Mohara C, Pourcel L, Derumeaux H, BÃ©rard E, Bourrel R, Molinier L, Brefel-Courbon C. Clinical Impact and Cost-Effectiveness of an Education Program for PD Patients: A Randomized Controlled Trial. PLoS One. 2016 Sep 29;11(9):e0162646. doi: 10.1371/journal.pone.0162646. eCollection 2016.</citation>
    <PMID>27685455</PMID>
  </reference>
  <reference>
    <citation>Ory Magne F, Arcari C, Canivet C, Sarrail M, Fabre MH, Mohara C, Brefel Courbon C. [A therapeutic educational program in Parkinson's disease: ETPARK]. Rev Neurol (Paris). 2014 Feb;170(2):128-33. doi: 10.1016/j.neurol.2013.08.007. Epub 2013 Nov 20. French.</citation>
    <PMID>24267951</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic education</keyword>
  <keyword>Parkinson Disease</keyword>
  <keyword>Socials representations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

